Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible-Reference-Cited by-同舟云学术

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible

Published:2020-08-25 Issue:2 Volume:1 Page:481-488
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Sonneveld Pieter¹,Mateos María‐Victoria²,Alegre Adrian³,Facon Thierry⁴,Hulin Cyrille⁵,Hashim Mahmoud⁶,Vincken Talitha⁶,Kampfenkel Tobias⁷,Cote Sarah⁸,He Jianming⁸^ORCID,Lam Annette⁸,Moreau Philippe⁹

Affiliation:

1. Erasmus MC Cancer Institute Rotterdam Netherlands

2. University Hospital of Salamanca/IBSAL Salamanca Spain

3. Hospital Universitario de La Princesa Madrid Spain

4. University of Lille, CHU Lille, Service des Maladies du Sang Lille France

5. Hospital Center University De Bordeaux Bordeaux France

6. Ingress Health Rotterdam Netherlands

7. Department of Oncology Janssen Research & Development, LLC Netherlands

8. Janssen Global Services, LLC Raritan NJ USA

9. Nantes University Hospital Hotel‐Dieu, Service Hematologie Nantes France

Publisher

Wiley